---
title: "Avacopan Readjudication Confirms Noninferiority for ANCA-Associated Vasculitis Remission"
id: "medrxiv-0-avacopan-for-the-treatment-of-anca-associated-vasculitis-the-primary-endpoints"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-0-avacopan-for-the-treatment-of-anca-associated-vasculitis-the-primary-endpoints"
content_type: "clinical_feed_article"
specialty: "Rheumatology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.08.13.26360315v1?rss=1"
published_at: "2026-08-14T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Avacopan Readjudication Confirms Noninferiority for ANCA-Associated Vasculitis Remission
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-0-avacopan-for-the-treatment-of-anca-associated-vasculitis-the-primary-endpoints
- **Specialty:** [Rheumatology](https://medichelpline.com/clinical-feed/rheumatology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.08.13.26360315v1?rss=1)
- **Published At:** 2026-08-14T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The phase 3 ADVOCATE trial evaluated oral **avacopan** 30 mg twice daily versus a scheduled oral **prednisone** taper, each with rituximab- or cyclophosphamide-based standard of care, in patients with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA). - Concerns about the original 2019 primary endpoint adjudication prompted a blinded independent readjudication in 2026 by the Duke Clinical Research Institute Clinical Events Classification group using procedures aligned with the original charter. - The primary endpoints were **remission at week 26** and **sustained remission at week 52**, adjudicated using the Birmingham Vasculitis Activity Score (BVAS) and definitions of relapse and remission. - In the 2026 readjudication (intent-to-treat, n=330), remission at week 26 was 68.1% (113/166) with avacopan and 67.1% (110/164) with prednisone (adjusted difference 2.2%; 95% CI, −7.5 to 11.9), confirming noninferiority per the prespecified −20 percentage point margin. - Sustained remission at week 52 in 2026 was 61.4% (102/166) with avacopan versus 52.4% (86/164) with prednisone (adjusted difference 9.8%; 95% CI, −0.3 to 19.9); this numeric advantage did not meet statistical superiority. - Results are similar to the 2019 adjudication: week 26 remission 72.3% vs 70.1% (adjusted difference 3.4%; 95% CI, −6.0 to 12.8) and week 52 sustained remission 65.7% vs 54.9% (adjusted difference 12.5%; 95% CI, 2.6 to 22.3). - Concordance between 2019 and 2026 adjudications was high: 95.2% for remission and 93.6% for sustained remission. - The readjudication confirms **noninferiority of avacopan** at weeks 26 and 52 while noting a median 81% reduction in glucocorticoid exposure in the avacopan group compared with the prednisone taper group. - Although a consistent numerical advantage for avacopan at week 52 was present in both adjudications, statistical superiority was not achieved in the 2026 re-analysis. - The report details competing interests for multiple authors and states that trial data are not publicly available; qualified researchers may request access under governance procedures.
## Clinical Analysis & Structured Key Points
[](https://www.medrxiv.org/cdn-cgi/content?id=2dfdrRTiIqcXpGbU1NwnO9vyWmEizxT6WXnw8s.AQrg-1786744701.754909-1.2.1.1-_NADfo0KKog.vyu2hy5_qkcnOU.tE2tMHibuygwWEvFOMaUFnZWk0.CVJekZYfcL) [Skip to main content](https://www.medrxiv.org/content/10.64898/2026.08.13.26360315v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # Avacopan for the Treatment of ANCA-Associated Vasculitis: The Primary Endpoints Readjudication David Jayne, [ View ORCID Profile](http://orcid.org/0000-0001-9284-7345)Peter A. Merkel, Xinyu Tang, Zachary S. Wallace, Casey P. Norris, Nikieia Hayden, Sumita Bhatta, Renato D. Lopes, Amy Stallings doi: https://doi.org/10.64898/2026.08.13.26360315 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. David Jayne 1 Department of Medicine, University of Cambridge, Cambridge, UK; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=David%2BJayne%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Jayne%20D&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ADavid%2BJayne%2B) Peter A. Merkel 2 Division of Rheumatology, Department of Medicine, Division of Epidemiology, Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, PA, USA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Peter%2BA.%2BMerkel%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Merkel%20PA&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3APeter%2BA.%2BMerkel%2B) * [ORCID record for Peter A. Merkel](http://orcid.org/0000-0001-9284-7345 "Open in new tab") * For correspondence: pmerkel@upenn.edu Xinyu Tang 3 Amgen Inc., Thousand Oaks, CA, USA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Xinyu%2BTang%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Tang%20X&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AXinyu%2BTang%2B) Zachary S. Wallace 3 Amgen Inc., Thousand Oaks, CA, USA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Zachary%2BS.%2BWallace%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Wallace%20ZS&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AZachary%2BS.%2BWallace%2B) Casey P. Norris 4 Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Casey%2BP.%2BNorris%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Norris%20CP&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ACasey%2BP.%2BNorris%2B) Nikieia Hayden 4 Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Nikieia%2BHayden%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Hayden%20N&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ANikieia%2BHayden%2B) Sumita Bhatta 3 Amgen Inc., Thousand Oaks, CA, USA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Sumita%2BBhatta%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Bhatta%20S&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ASumita%2BBhatta%2B) Renato D. Lopes 4 Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Renato%2BD.%2BLopes%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Lopes%20RD&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ARenato%2BD.%2BLopes%2B) Amy Stallings 5 Duke Clinical Research Institute, Duke University School of Medicine, Division of Allergy and Immunology, Department of Pediatrics, Durham, NC, USA * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Amy%2BStallings%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Stallings%20A&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AAmy%2BStallings%2B) * [Abstract](https://www.medrxiv.org/content/10.64898/2026.08.13.26360315v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1278781/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.08.13.26360315v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1278781/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.08.13.26360315v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1278781/1) * [Supplementary material](https://www.medrxiv.org/content/10.64898/2026.08.13.26360315v1.supplementary-material)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_data/node:1278781/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.08.13.26360315v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1278781/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.08.13.26360315v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1278781/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract **Background** The phase 3 ADVOCATE trial evaluated the efficacy and safety of avacopan in patients with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA). Concerns raised regarding the 2019 primary endpoint adjudication process prompted a blinded, independent readjudication of all participants' primary outcomes, the results of which are described here. **Methods** Patients with GPA or MPA were randomized 1:1 to receive oral avacopan 30 mg twice daily or oral prednisone on a scheduled taper, each in combination with rituximab- or cyclophosphamide-based standard of care. In 2026, the Duke Clinical Research Institute Clinical Events Classification group conducted an independent, blinded committee re-adjudicated the Birmingham Vasculitis Activity Score (BVAS), relapse, and remission from weeks 26 through 52 using procedures aligned with the original adjudication charter. The primary endpoints were remission at week 26 and sustained remission at week 52. As per the original analysis plan, noninferiority and superiority were declared if the lower bounds of the 95% confidence interval (CI) for the difference in the primary outcome rates between avacopan and a prednisone taper were greater than −20.0 and 0.0 percentage points, respectively. **Results** Among 330 participants in the intent-to-treat population, remission at week 26 was achieved by 68.1% (113/166) and 67.1% (110/164) of participants in the avacopan and prednisone taper groups, respectively, in the 2026 readjudication (adjusted difference: 2.2%; 95% CI, −7.5, 11.9), compared with 72.3% (120/166) and 70.1% (115/164) in the 2019 primary outcome adjudication (adjusted difference: 3.4%; 95% CI, −6.0, 12.8). Sustained remission at week 52 was achieved by 61.4% (102/166) and 52.4% (86/164) of participants, respectively, in the 2026 readjudication (adjusted difference: 9.8%; 95% CI, −0.3, 19.9), compared with 65.7% (109/166) and 54.9% (90/164) in the 2019 readjudication (adjusted difference: 12.5%; 95% CI, 2.6, 22.3). Concordance between the 2019 and 2026 adjudications was 95.2% for remission and 93.6% for sustained remission. **Conclusion** The re-analysis of ADVOCATE based on the 2026 readjudication further supports the efficacy of avacopan for GPA/MPA. Non-inferiority of avacopan versus a prednisone taper was confirmed at weeks 26 and 52 despite a median 81% reduction in glucocorticoid exposure observed in the avacopan versus prednisone taper groups. While a consistent numerical difference favoring avacopan at week 52 was observed in the 2019 and 2026 analyses, this difference did not reach statistical superiority. ### Competing Interest Statement David Jayne reports receiving honoraria or consulting fees from Alentis, Amgen, Astra-Zeneca, Autolus, BIOGEN, Boehringer, ClimbBio, CSL Vifor, Fate, GSK, Jade, Kissei, Novartis, Otsuka, and UCB. Peter A. Merkel reports receiving funds for the following activities in the past 2 years: Consulting: AbbVie, Alexion, Amgen, ArGenx, AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Lifordi, Lilly, Melodia, Merge, Mirador, Neutrolis, Novartis, NS Pharma, Otsuka, Protallix, Q32, Quell, Regeneron, Sanofi, Sparrow, Zura. Research Support: AbbVie, Amgen, AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Electra, GlaxoSmithKline, Neutrolis, Q32, and Takeda. Stock options: Q32, Lifordi, Neutrolis, Serpass, and Sparrow. Royalties: UpToDate. Renato D. Lopes reports research grants or contracts from Bristol Myers Squibb, GlaxoSmithKline, Pfizer, Novartis, Ionis Pharmaceuticals Inc, Regeneron Pharmaceuticals Inc, Alnylam, Roche, Bayer, VeraDermics, Priovant Therapeutics Basilea Pharmaceutica, Theravance Biopharma Inc, Cytokinetics Inc. Funding for educational activities or lectures from Pfizer, Novartis, Novo Nordisk, and Bristol Myers Squibb. Funding for consulting from Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Novo Nordisk, Novartis, and Pfizer. Xinyu Tang, Zachary S. Wallace and Sumi Bhatta are employees of, and hold stock in, Amgen, Inc. Amy Stallings, Casey P. Norris, Nikieia Hayden do not have any conflict of interests. ### Clinical Trial NCT02994927 ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The following IRBs provided ethics approval to the original phase 3 trial: 1. Advarra Institutional Review Board: 6940 Columbia Gateway Drive, Suite 110 Columbia, MD 21046, USA 2. Partners Human Research Committee 399 Revolution Drive, Suite 710 Somerville, MA 02145, USA 3. Schulman Institutional Review Board, 4445 Lake Forest Drive, Suite 300 Cincinnati, OH 45242, USA 4. Brany Institutional Review Board: 1981 Marcus Avenue, Suite 210 Lake Success, NY 11042, USA 5. Western Institutional Review Board: 1019 39th Avenue SE Suite 120, Puyallup, WA 98374, USA 6. University of Kansas Medical Center: 3901 Rainbow Blvd. Kansas City, KS 66160, USA 7. University of Chicago Institutional Review Board: 5841 S. Maryland Ave. MC7132, I-625 Chicago, IL: 60637, USA "8. Columbia University Medical Center Institutional Review Board 154 Haven Ave., 1st Floor New York, NY 10032, USA" 9. University of California San Francisco Committee on Human Research: 3333 California Street, Suite 315 San Francisco, CA 94118, USA 10. Lifespan Research Protection Office: CORO West, Suite 1300 One Hoppin Street Providence, Rhode Island 02903, USA 11. Mayo Clinic Institutional Review Board: 200 First Street SW Rochester, MN 55905, USA "12. Georgetown-Howard Universities Center for Clinical and Translational Science Institutional Review Board 3900 Reservoir Road NW, SW 104 Med Dent Building Washington, DC 20007, USA" 13. Human Research Protection Office: Washington University in St. Louis, 660 S. Euclid Ave., Campus Box #8089, St. Louis, MO 63110, USA 14. Chesapeake Research Review, Inc.: 6940, Columbia Gateway Drive, Suite 110 Columbia, MD 20146-3403, USA 15. NYU Winthrop Hospital, Institutional Review Board: 222 Station Plaza North Suite 521 Mineola, NY 11501, USA 16. Cedars-Sinai Medical Center Institutional Review Board: 6500 Wilshire Blvd. Suite 1800 Beverly Hills, CA 90048, USA 17. Office of the Human Research Protection Program: 10889 Wilshire Blvd, Suite 820, Los Angeles, CA 90095-1406, USA 18. John Hopkins Medicine Institutional Review Board: 1620 McElderry Street Reed Hall B-130 Baltimore, Maryland 21205-1911, USA 19. The Cleveland Clinic Foundation Institutional Review Board: 9500 Euclid Ave. OS-1 Cleveland, OH 44195, USA 20. University of Utah Institutional Review Board: 75 South 2000 East, Salt Lake City, Utah 84112, USA 21. Boston University Medical Campus Institutional Review Board 560 Harrison Ave, Third Floor, Suite 300 Boston, MA 02118, USA "22. East Carolina University - University & Medical Center Institutional Review Board 4N70 Brody Medical Sciences Building, MailStop 682 600 Moye Boulevard Greenville, NC 27834, USA" "23. University of Kentucky Office of Research Integrity 315 Kinkead Hall Lexington, KY 40506, USA" "24. University of Minnesota Human Research Protection Program 420 Delaware St SE, D528 Mayo Memorial Building, MMC 820 Minneapolis, MN 55455, USA" 25. Mount Sinai Ethics Review Board 700 University Avenue Suite 8-600 Toronto, ON MSG 1Z5, Canada "26. Conjoint Health Research Ethics Board: 2500 University Drive NW 3rd Floor MacKimmie Library Tower Calgary, Alberta T2N 1N4, Canada" "27. Comite d'ethique de la recherche du CIUSSS de l'Est-de-l'Ile-de-Montreal 5415 Boul de l'Assomption, Suite 4158, 4th floor, Pavillon Rachel-Tourigny, Montreal., Quebec HlT2M4, Canada" "28. CIUSSS de l'Est-de-l'ile-de-Montreal - installation Hopital Maisonneuve-Rosemont 5415 boul. l'Assomption, Montreal, Quebec HlT 2M4, Canada" 29. UBC PHC REB: 10th Floor - 1190 Hornby Street, Vancouver, BC V67 2K5 "30. Hamilton Integrated Research Ethics Board 293 Wellington Street North Hamilton, Ontario L8L8E7, Canada" "31. Le Comite d'ethique de la recherche du crusss de l'Estrie - CHUS: 3001, 12e avenue Nord Sherbrooke, Quebec J1H5N4, Canada" "32. Comite d'ethique de la recherche du CIUSSS de l'Est-de-l'ile-de Montreal: 66, Sainte-Catherine Est Montreal, Quebec H2X IK6, Canada" "33. Comite Ethique de la recherche du CIUSSS de l'Est-de-l'Ile -de-Montreal 5415,Boulevard de l'Assomption Montreal, Quebec H1T2M4, Canada" 34. Ethikkommission der Medizinischen Universitat Graz: LKH-Universitatsklinikum, Auenbruggerplatz 2 Graz, A-8036, Austria "35. Comite d'Ethique Hospitalo-Facultaire Saint-Luc: Avenue Hippocrate 55.14, Tour Harvey - Niveau 0 Bruxelles 1200, Belgium" "36. Comite d'Ethique Hospitalo-Facultaire Saint-Luc: Promenade de l' Alma 51 Bte Bl.43.03 1200 Bruxelles, Belgium" 37. CEC: Eticka komise Fakultni nemocnice Kralovske Vinohrady, Srobarova 1150/50, Praha 10 100 34, Czech Republic 38. De Videnskabsetiske Komiteer for Region Hovedstaden, Kongens Vaenge 2 Hillerod,3400, Denmark 39. Comite de Protection des Personnes Ile-De-France IV: Hopital Saint Louis - Porte 5 du Carre Historique, 1 avenue Claude Vellefaux, Paris 75475 cedex 10, France 40. Ethikkommission der Medizinischen Fakultat Heidelberg: Alte GlockengieBerei 11/1, Heidelberg BW 69115, Germany 41. Research Ethics Committee SJH/AMNCH Tallaght Hospital, Dublin 24, Ireland 42. CEC - Comitato Etico Regionale della Liguria - Sezione 3, Largo Rosanna Benzi 10 Genova, GE 16132, IT 43. Comitato Etico Regionale della Liguria - Sezione 3, IRCCS AOU San Martino 1ST Largo Rosanna Benzi 10 Genova, NAP 16132, Italy 44. Comitato Etico Regionale della Liguria - Sezione 3, Largo Rosanna Benzi 10, Genova GE 16132, Italy 45. METc UMCG: Hanzeplein 1, Groningen, Groningen 9713 GZ, The Netherlands "46. Regional komite for medisinsk og helsefaglig forskningsetikk (REK) Sor-ost: Gullhaugveien 1-3 Oslo 0484, Norway" 47. Comite Autonomico de Etica de la Investigacion de Galicia (CAEI de Galicia): Edificio Administrativo San Lazaro, C/ San Lazaro, s/n,Santiago de Compostela, A Coruna 15703, Spain "48. Regionala Etikprovningsnamden i Stockholm Widenstromska huset, Tomtebodavagen 18A Solna, 171 65, Sweden" 49. East of England - Cambridge South Research Ethics Committee: The Old Chapel, Royal Standard Place Nottingham, NG1 6FS, UK 50. East of England - Cambridge South Research Ethics Committee, The Old Chapel, Royal Standard Place , London, NG1 6PS, UK 51. Central Adelaide Local Health Network (CALHN) HREC: Roma Mitchell House, Level 3, 136 North Terrace, Adelaide, SA 5000, Australia 52. UnitingCare Health Human Research Ethics Committee: Ground Floor, Moorlands House, 451 Coronation Drive, Auchenflower, QLD 4066, Australia "53. Sir Charles Gairdner Hospital Human Research Ethics Committee: Hospital Avenue Nedlands, WA 6009, Australia" 54. Health and Disability Ethics Committees 133 Molesworth Street, PO Box 5013 Wellington 6011, New Zealand 55. Ethikkommission Ostschweiz Haus 37: St. Gallen, St. Gallen 9007, Switzerland "56. Egeszsegugyi Tudomanyos Tanacs Klinikai Farmakologiai Etikai Bizottsaga: Alkotmany u. 25. Budapest 1054 Hungary" 57. Kobe University Hospital Institutional Review Board: 7-5-2,Kusunoki-Cho,Chuo-Ku Kobe-City, Hyogo 650-0017, Japan "58. Okayama University Hospital Institutional Review Board: 2-5-1 Shikata-cho, Kita-ku Okayama-city, Okayama 700-8558, Japan" 59. National Hospital Organization Nagoya Medical Center Institutional Review Board: 4-1-1 Sannomaru Naka-ku, Nagoya-city, Aichi 460-0001, Japan "60. Juntendo University Shizuoka Hospital Institutional Review Board: 1129, Nagaoka Izunokuni-shi, Shizuoka 410-2295, Japan" "61. University of Miyazaki Hospital Institutional Review Board: 5200 Kiyotakecho Kihara Miyazaki-city, Miyazaki 889-1692 Japan" 62. Shimane University Hospital Clinical research review board: 89-1, Enya-cho Izumo, Shimane 693-8501, Japan 63. Saitama Medical University Hospital Institutional Review Board: 38, Morohongo, Irumagun Moroyamamachi Saitama 350-0495, Japan "64. Kagawa University Hospital Institutional Review Board: 1750-1, Ikenobe, Miki-cho Kita-gun, Kagawa 761-0793, Japan" 65. Hiroshima University Hospital Institutional Review Board, Kasumi 1-2-3 Minami-ku Hiroshima-city, Hiroshima 734-8551, Japan 66. Institutional Review Board of Saitama Medical Center, 1981 Kamoda Kawagoe, Saitama
## Related Clinical Research

- [Secukinumab Phase 3 Trial Shows Higher Remission and Lower Glucocorticoid Use in Relapsing Polymya](https://medichelpline.com/clinical-feed/pubmed-42234540.md) (DOI: 10.1056/NEJMoa2602567)
- [Apoptosis-Related Genes WNT1 and S100A8 Link Inflammatory Bowel Disease and Osteoporosis](https://medichelpline.com/clinical-feed/plos-one-1-apoptosis-related-genes-bridge-inflammatory-bowel-disease-and-osteoporosis-a.md)
- [Infections and Hypogammaglobulinemia with Low‑Dose Rituximab in Myasthenia Gravis — Full Text Not](https://medichelpline.com/clinical-feed/frontiers-in-immunology-18-infections-and-hypogammaglobulinemia-in-myasthenia-gravis-patients-receiving.md)
- [From Idiopathic Recurrent Pericarditis to Behçet’s Disease: IL-1–Driven Autoinflammatory Case Repo](https://medichelpline.com/clinical-feed/frontiers-in-immunology-12-case-report-from-idiopathic-recurrent-pericarditis-to-systemic-beh-et-s-disease.md)
- [Clinical characteristics and outcomes of pediatric B-ALL with MEF2D gene rearrangement](https://medichelpline.com/clinical-feed/pubmed-42527140.md) (DOI: 10.3760/cma.j.cn112140-20251230-01163)

## Navigation
- [← Back to Rheumatology Feed](https://medichelpline.com/clinical-feed/rheumatology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.